跳至主要内容
临床试验/KCT0001981
KCT0001981招募中未知

Application and Effectiveness Analysis of Community-Based Diabetes Prevention Program in Korea

The Catholic University of Korea0 个研究点目标入组 420 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
420

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
30(Year) 至 64(Year)(—)
性别
All

入选标准

  • Adults 30-64 years
  • -Body mass index (BMI) = 23 kg/m2
  • -Impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) according to the criteria of the World Health Organization (WHO)

排除标准

  • - Subjects who diagnosed with diabetes mellitus
  • · Fasting plasma glucose (FPG) = 126 mg/dL or HbA1c = 6.5%
  • · 2-h plasma glucose (PG) = 200 mg/dL based on 75-g OGTT
  • - Subjects who previously admitted for cardiovascular disease within 6 months
  • - Subjects who had a history of aortic stenosis, left bundle block or third degree atrioventricular block or who had a pacemaker
  • - Subjects who previously diagnosed with renal disease (creatinine = 1.4 mg/dl in men, or = 1.3 mg/dl in women)
  • - Subjects who previously diagnosed with malignant disease within 5 years
  • - Subjects who have anemia (hematocrit < 36 % in men or < 33 % in women)
  • - Subjects who have hepatitis or liver cirrhosis
  • - Subjects who have acute gastrointestinal disease
  • - Subjects who have a plan of surgery in 3-6 months
  • - Subjects who have chronic infection (human immunodeficiency virus, tuberculosis, etc.)
  • - Subjects with pulmonary disease, who need supplemental oxygen or bronchodilator therapy
  • - Subjects who cannot communicate effectively in Korean
  • - Subjects who do not want to receive any kind of intervention.
  • - Subjects who are pregnant or had delivery within 3 months or have a plan of pregnancy
  • - Subjects who have major psychiatric disease or heavy alcoholics
  • - Subjects who cannot walk 400 meters in 10 minutes
  • - Subjects who participate in different clinical studies or may not understand this study process.
  • - Subjects who had taken drugs or were clinical state described below
  • · Niacin, Glucocorticoids
  • · Selective serotonin re-uptake inhibitors in weight-reduction dose
  • · Other weight-loss medications
  • · Untreated thyroid disease or cushing's syndrome, acromegaly
  • · Fasting triglyceride level > 600 mg/dl despite therapy

研究者

相似试验